Table of Contents
1 Methodology, Objectives and Executive Summary
- 1.1 Report Objectives
- 1.2 Research Methodology
- 1.3 Executive Summary
2 Challenges and Issues In the Protein Therapeutics Market
- 2.1 Pricing
- 2.2 Drug Delivery
- 2.3 Manufacturing Capacity
- 2.4 The Biogeneric Threat
- 2.4.1 Loss of Patent Protection
- 2.4.2 High Manufacturing Costs
- 2.4.3 Lack of Adequate Legislation
- 2.4.4 Restrictive Cost of Biotech Generics
- 2.4.5 Biogeneric Landscape
3 Overview of the Monoclonal Antibody Class
- 3.1 History of MAbs
- 3.2 The Production of MAbs
- 3.3 How do Monoclonal Antibodies Work?
- 3.4 Types of Monoclonal Antibodies
- 3.4.1 Human Antibodies
- 3.4.2 Humanized Antibodies (CDR-Grafted)
- 3.4.3 Chimeric Antibodies
- 3.4.4 Murine Antibodies
4 Barriers to Successful Treatment with Monoclonal Antibodies
- 4.1 Human Anti-Mouse Response
- 4.2 Side Effects
- 4.3 Nature of Disease
- 4.4 Manufacturing Capacity Limitations
- 4.4.1 Manufacturing Costs
- 4.4.2 Contract Manufacturing as an Alternative
- 4.4.3 Potential of Transgenic Protein Production
5 Therapeutic Applications for Monoclonal Antibodies
- 5.1 Cancer
- 5.1.1 Rituxan (rituxumab)
- 5.1.2 Herceptin (trastuzumab)
- 5.1.3 Campath (alemtuzumab)
- 5.1.4 Mylotarg (gemtuzumab ozogamicin)
- 5.1.5 Zevalin (ibritumomab tiuxetan)
- 5.1.6 Erbitux (cetuximab)
- 5.1.7 Bexxar (tositumomab)
- 5.1.1.8 Avastin (bevacizumab)
- 5.2 Autoimmune/Inflammatory Diseases
- 5.2.1 Rheumatoid Arthritis
- 5.2.1.1 Remicade (infliximab)
- 5.2.1.2 Humira (adalimumab)
- 5.2.2 Inflammatory Bowel Disease
- 5.2.2.1 Remicade (infliximab)
- 5.2.3 Multiple Sclerosis
- 5.2.3.1 Tysabri (natalizumab)
- 5.2.4 Psoriasis
- 5.2.4.1 Raptiva (efalizumab)
- 5.2.5 Asthma
- 5.2.6 Age-Related Macular Degeneration (AMD)
- 5.2.6.1 Lucentis (ranibizumab)
- 5.2.7 Transplant Rejection
- 5.2.7.1 Simulect (basiliximab)
- 5.2.7.2 Zenapax (daclizumab)
- 5.2.7.3 Orthoclone OKT-3 (muromonab CD3)
- 5.2.8 Other Conditions
- 5.2.8.1 Percutaneous coronary intervention (PCI)
- 5.2.8.1.1 ReoPro (abciximab)
- 5.2.8.2 Lower Respiratory Tract Disease
- 5.2.8.2.1 Synagis (palivizumab)
6 Market Analysis
- 6.1 Commercial Market Size
- 6.2 Segmentation by Therapeutic Category
- 6.2.1 Cancer
- 6.2.2 Autoimmune/Inflammatory
- 6.3 Market Share by Country/Region
- 6.4 Key Product Sales
- 6.5 Market Share by Company
- 6.6 Market Outlook
- 6.6.1 Drivers
- 6.6.2 Restraints
- 6.6.3 Financial Forecast
7 MAbs Innovation
- 7.1 MAb Structure Innovation
- 7.1.1 Immunogenicity
- 7.1.2 Effector Function
- 7.1.3 Antibody Size and Structure
- 7.1.4 Affinity
- 7.2 MAbs Drug Delivery Innovation
- 7.2.1 Inhaled MAb Delivery
- 7.2.2 Oral MAb Delivery
- 7.3 MAbs Technology Innovation
8 Emerging Monoclonal Antibody Therapies
- 8.1 Cancer
- 8.1.1 ABX-EGF (panitumumab)
- 8.1.2 Cotara (TNT-1)
- 8.1.3 Rencarex (WX-G250)
- 8.1.4 OvaRex
- 8.1.5 MDX-010
- 8.1.6 HuMax-CD4
- 8.1.7 Avastin
- 8.1.8 HuMax-CD20
- 8.2 Autoimmune/Inflammatory
- 8.2.1 Humira
- 8.2.2 Rituxan
- 8.2.3 Actemra (tocilizumab)
- 8.2.4 HuMax-CD20
- 8.2.5 Campath
- 8.2.6 CDP 870 (certolizumab pegol)
- 8.2.7 Remicade
- 8.2.8 Tysabri
- 8.2.9 AMG 412
- 8.2.10 LymphoCyde
- 8.2.11 SB 240563
- 8.2.12 MLN 1202
- 8.2.13 ABT 875
- 8.2.14 CNTO 148
- 8.3 Other Conditions
- 8.3.1 Segard
- 8.3.2 Anti-C5 Antibody
- 8.3.3 5G1.1
- 8.3.4 Aurograb
- 8.3.5 AMG 162
9 Key Companies in the MAbs Market
- 9.1 Abbott Laboratories
- 9.2 Biogen Idec
- 9.3 Cambridge Antibody Technology
- 9.4 Chugai Pharmaceutical
- 9.5 Dyax
- 9.6 Elan Corporation
- 9.7 Genentech
- 9.8 Genmab
- 9.9 Genzyme
- 9.10 Human Genome Sciences
- 9.11 ImClone
- 9.12 Immunomedics
- 9.13 InNexus Biotechology
- 9.14 Johnson & Johnson
- 9.15 Medarex
- 9.16 MedImmune
- 9.17 PDL Biopharma
- 9.18 Raven Biotechnologies
- 9.19 Regeneron Pharmaceuticals
- 9.20 Roche
- 9.21 Seattle Genetics
- 9.22 Xencor
- 9.23 Xoma
Appendix
Tables
- Table 3.1 Mammalian Antibody Types
- Table 4.1 Principal Methods of Creating Transgenic Animals
- Table 4.2 Pros and Cons of Transgenic Plants
- Table 4.3 Companies Involved in the Field of Transgenic Protein Technology
- Table 5.1 Monoclonal Antibody Therapies on the Market 2006
- Table 5.2 Monoclonal Antibodies on the Market for the Treatment of Cancer
- Table 5.3 Monoclonal Antibodies on the Market for the Treatment of
Autoimmune/Inflammatory Conditions
- Table 5.4 Description of IBD
- Table 5.5 Types of MS
- Table 5.6 Types of Transplant Rejection
- Table 5.7 Antibodies Used to Prevent Transplant Rejection
- Table 6.1 Leading Monoclonal Antibody Products, by Sales 2000-2006 (US$mn)
- Table 6.2 US Sales of Monoclonal Antibodies, Cancer Indications 2000-2006
(US$mn)
- Table 6.3 Monoclonal Antibody Sales, Autoimmune/Inflammatory Indications,
1999-2006 (US$mn)
- Table 6.4 Monoclonal Antibody Market Share (2005), by Country/Region
- Table 6.5 Global Sales of Herceptin 2000-2006 (US$mn)
- Table 6.6 Global Sales of Avastin 2004-2006 (US$mn)
- Table 6.7 Global Sales of Rituxan 2003-2006 (US$mn)
- Table 6.8 Global Sales of Humira 2003-2006 (US$mn)
- Table 6.9 Global Sales of Remicade 2000-2006 (US$mn)
- Table 6.10 Global Sales of Raptiva 2003-2006 (US$mn)
- Table 6.11 Global Sales of Xolair 2003-2006 (US$mn)
- Table 6.12 Financial Forecast for the Monoclonal Antibody Market 2005-2010
(US$bn)
- Table 6.13 Forecast Sales of Leading Monoclonal Antibody Products
2005-2010 (US$mn)
- Table 7.1 Key Areas of MAb R&D Efforts
- Table 7.2 Targeted Therapy Approaches
- Table 8.1 Avastin Status in Clinical Trials
- Table 8.2 Types of ACR Response Criteria
- Table 9.1 Biogen Idec' s Mab Pipeline
- Table 9.2 CAT' s Clinical Pipeline
- Table 9.3 Immunomedics' Key Product Pipeline
- Table 9.4 Medarex' s MAb Pipeline
- Table 9.5 Roche' s Mab Products
Graphs
- Graph 6.1 Leading Monoclonal Antibody Products by 2005 Sales (US$mn)
- Graph 6.2 Monoclonal Antibody Market Share by Therapeutic Category (2005)
- Graph 6.3 Annual Percentage Growth of US Sales of Monoclonal Antibodies,
Cancer Indications 2000-2005
- Graph 6.4 Annual Growth of Monoclonal Antibody Sales,
Autoimmune/Inflammatory Indications, 2001-2005
- Graph 6.5 Monoclonal Antibody Market Share, US vs Rest of World
- Graph 6.6 Monoclonal Antibody Market Share, by Top Five Products 2005
- Graph 6.7 Leaders in the Monoclonal Antibody Therapy Market, 2005 Market
Share
- Graph 6.9 Forecast of Annual Percentage Sales Growth of Leading Monoclonal
Antibody Products 2005-2010
- Graph 6.8 Total Forecast Sales of Leading Monoclonal Antibody Products
2005-2010 (US$mn)
Diagrams
Figure 7.1 Modified Antibodies
|
Related Report
|
View Cart
